Rapport Therapeutics, Inc. (RAPP) intrinsic value & 10-year financials
Rapport Therapeutics, Inc. (RAPP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $27.57
- Market cap
- $1.1B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -35.0%
- Free cash flow (FY2025)
- -$88.1M
RAPP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$111.5M | -$2.86 | -$88.1M | — | -36.3% |
| FY2024 | — | -$78.3M | -$3.78 | -$67.2M | — | -107.1% |
| FY2023 | — | -$34.8M | -$1.65 | -$28.8M | — | 38.4% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Rapport Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Rapport Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -35.0% ROIC.
Rapport Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Rapport Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.